Crinetics Pharmaceuticals, Inc. — Director's Dealing 2018

Jul 21, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2018-07-20

Reporting Person: 5AM Ventures IV, L.P. (10% Owner)
Reporting Person: 5AM Co-Investors IV, L.P. (10% Owner)
Reporting Person: 5AM Partners IV, LLC (10% Owner)
Reporting Person: ROCKLAGE SCOTT M (10% Owner)
Reporting Person: DIEKMAN JOHN D (10% Owner)
Reporting Person: Schwab Andrew J. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-20	Common Stock	C	2797635	—	Acquired	2797635	Indirect
2018-07-20	Common Stock	C	451274	—	Acquired	3248909	Indirect
2018-07-20	Common Stock	C	116567	—	Acquired	116567	Indirect
2018-07-20	Common Stock	C	18802	—	Acquired	135369	Indirect
2018-07-20	Common Stock	P	110400	$17	Acquired	3359309	Indirect
2018-07-20	Common Stock	P	4600	$17	Acquired	139969	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-20	Series A Preferred Stock	$	C	9204220	Disposed		Common Stock (2797635)	Indirect
2018-07-20	Series B Preferred Stock	$	C	1484690	Disposed		Common Stock (451274)	Indirect
2018-07-20	Series A Preferred Stock	$	C	383507	Disposed		Common Stock (116567)	Indirect
2018-07-20	Series B Preferred Stock	$	C	61861	Disposed		Common Stock (18802)	Indirect

Footnotes

F1: These securities are held of record by 5AM Ventures IV, L.P. ("Ventures IV"). Following the transactions reported herein, 3,359,309 shares of Common Stock are held of record by Ventures IV.

F2: These securities are held of record by 5AM Co-Investors IV, L.P. ("Co-Investors IV"). Following the transactions reported herein, 139,969 shares of Common Stock are held of record by Co-Investors IV.

F3: 5AM Partners IV, LLC ("Partners IV") is the sole general partner of Ventures IV and Co-Investors IV. Dr. John Diekman, Andrew J. Schwab and Dr. Scott M. Rocklage, are the managing members of Partners IV, and have shared voting and investment power over the shares beneficially owned by Ventures IV and Co-Investors IV. Each of Partners IV, Dr. Diekman, Mr. Schwab, and Dr. Rocklage disclaims beneficial ownership of such shares except to the extent of its or their pecuniary interest therein.

F4: Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into the Issuer's Common stock on a 3.29-for-1 basis, for no additional consideration, upon the closing of the Issuer's initial public offering. The Series A Preferred Stock and the Series B Preferred Stock had no expiration date.